Skip to main content

Almirall

Almirall SA is a Spanish biopharmaceutical company specializing in medical dermatology and skin health therapeutics. The company researches, manufactures, and commercializes prescription therapies for psoriasis, actinic keratosis, atopic dermatitis, and acne, highlighted by Ilumetri (tildrakizumab), Klisyri, and Wynzora. Main revenue drivers comprise global commercial sales of prescription dermatological pharmaceuticals alongside licensing milestone receipts and active pharmaceutical ingredient sales. Almirall serves dermatologists, hospital networks, prescription pharmacies, and skin disease patients across Europe, North America, and Asia. The company holds a market-leading European position in prescription medical dermatology and inflammatory skin disease treatments. Headquartered in Barcelona, Spain, Almirall SA is listed on the Bolsa de Madrid.

4 of the funds FundTelligence covers report a position in Almirall.

Legal name
Almirall SA
Sector
Health Care
Country
Spain
Funds holding it
4

Funds holding Almirall

Loading...